Biohaven Pharmaceuticals

Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments for people with debilitating diseases. Following the acquisition of its CGRP migraine franchise by Pfizer in 2022, a new Biohaven was founded that same year to continue advancing innovative therapies. The company is building an extensive early-to-late-stage drug development portfolio across multiple therapeutic areas including immunology, obesity, neuroscience, and oncology. Biohaven has combined internal research capabilities with intellectual property licensed from leading institutions including Pfizer, Bristol-Myers Squibb, AstraZeneca, Yale University, and Massachusetts General Hospital. Headquartered in New Haven, Connecticut, Biohaven operates with approximately 200-500 employees and is guided by a patient-centric mission that prioritizes following science without limitations.